Xiao-long Wang
138 Xianlin Road
Nanjing, 210023, China
Nanjing, 210023, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery.
Journal: Journal of chemical information and modeling
Published: December 02, 2024
Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonists for Potential Treatment of Rheumatoid Arthritis.
Journal: Journal of medicinal chemistry
Published: November 15, 2024
Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations.
Journal: Journal of medicinal chemistry
Published: September 11, 2024
Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Journal: Drug development research
Published: July 24, 2024
Correction to "Discovery of RORγ Allosteric Fluorescent Probes and Their Application: Fluorescence Polarization, Screening, and Bioimaging".
Journal: Journal of medicinal chemistry
Published: March 26, 2024
Discovery of RORγ Allosteric Fluorescent Probes and Their Application: Fluorescence Polarization, Screening, and Bioimaging.
Journal: Journal of medicinal chemistry
Published: March 05, 2024
Design and synthesis 1H-Pyrrolo[2,3-b]pyridine derivatives as FLT3 inhibitors for the treatment of Acute myeloid Leukemia.
Journal: Bioorganic & medicinal chemistry
Published: December 11, 2023
Design and synthesis of selective FLT3 inhibitors via exploration of back pocket II.
Journal: Future medicinal chemistry
Published: January 18, 2023
Discovery of 4-(4-aminophenyl)-6-phenylisoxazolo[3,4-b]pyridine-3-amine derivatives as novel FLT3 covalent inhibitors for the intervention of acute myeloid leukemia.
Journal: Drug development research
Published: November 23, 2022
Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia.
Journal: Bioorganic & medicinal chemistry
Published: May 29, 2022
An efficient strategy for digging protein-protein interactions for rational drug design - A case study with HIF-1α/VHL.
Journal: European journal of medicinal chemistry
Published: May 24, 2021
Bufotenine and its derivatives: synthesis, analgesic effects identification and computational target prediction.
Journal: Chinese journal of natural medicines
Published: November 23, 2020
Last Updated: 09/26/2026